| Early intervention for diabetes in medical and surgical inpatients decreases hyperglycemia and hospital-acquired infections: a cluster randomized trial M Kyi, PG Colman, PR Wraight, J Reid, A Gorelik, A Galligan, S Kumar, ... Diabetes Care 42 (5), 832-840, 2019 | 60 | 2019 |
| FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment A Iravani, MM Osman, AM Weppler, R Wallace, A Galligan, A Lasocki, ... European journal of nuclear medicine and molecular imaging 47, 2776-2786, 2020 | 48 | 2020 |
| Diabetes associated with immune checkpoint inhibition: presentation and management challenges A Galligan, W Xu, S Fourlanos, A Nankervis, C Chiang, AM Mant, ... Diabetic Medicine 35 (9), 1283-1290, 2018 | 29 | 2018 |
| The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients A Lasocki, A Iravani, A Galligan Clinical Radiology 76 (5), 325-332, 2021 | 16 | 2021 |
| FDG PET/CT prognostic markers in patients with advanced melanoma treated with ipilimumab and nivolumab A Iravani, R Wallace, SN Lo, A Galligan, AM Weppler, RJ Hicks, S Sandhu Radiology 307 (3), e221180, 2023 | 7 | 2023 |
| Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus A Galligan, TM Greenaway Internal Medicine Journal 46 (5), 540-549, 2016 | 7 | 2016 |
| FDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma A Iravani, A Galligan, A Lasocki, R Wallace, A Weppler, GA Yeung, ... Journal of Nuclear Medicine 61 (supplement 1), 482-482, 2020 | 6 | 2020 |
| Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis A Galligan, R Wallace, B Krishnamurthy, TWH Kay, N Sachithanandan, ... Cancers 15 (24), 5803, 2023 | 4 | 2023 |
| Temporal trends in non-traumatic lower extremity amputations (LEAs) and their association with 12-month mortality in people with diabetes, 2004–2016 KV Kiburg, A Galligan, V Sundararajan, RJ MacIsaac Journal of Diabetes and its Complications 36 (7), 108221, 2022 | 3 | 2022 |
| The association between SARC‐F status and quality of life in High Risk Foot Clinic patients I Churilov, L Churilov, M Proctor, A Galligan, D Murphy, M Westcott, ... JCSM Clinical reports 4 (1), 1-10, 2019 | 3 | 2019 |
| Diabetes IN hospital–Glucose and Outcomes in the COVID‐19 pandemic (DINGO COVID‐19): the 2020 Melbourne hospital experience prior to novel variants and vaccinations RD Barmanray, JY Gong, M Kyi, D Kevat, MA Islam, A Galligan, ... Internal medicine journal 53 (1), 27-36, 2023 | 2 | 2023 |
| Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis A Galligan, A Iravani, A Lasocki, R Wallace, AM Weppler, ... Frontiers in Endocrinology 14, 1295865, 2023 | 1 | 2023 |
| Factors that predict glycaemic response to sodium‐glucose linked transporter (SGLT) inhibitors AL Harding, N Bediaga, A Galligan, PG Colman, S Fourlanos, ... Internal Medicine Journal 51 (4), 515-519, 2021 | 1 | 2021 |
| SUN-127 diagnostic challenges associated with the rising incidence of endocrine toxicity in the era of combination immunotherapy A Galligan, A Iravani, A Lasocki, R Wallace, A Weppler, G Au-Yeung, ... Journal of the Endocrine Society 4 (Supplement_1), SUN-127, 2020 | 1 | 2020 |
| OR32-06 opportunistic assessment of pituitary gland with routine MRI and PET/CT can guide in earlier and increased identification of hypophysitis in patients treated with … A Galligan, A Iravani, A Lasocki, R Wallace, A Weppler, G Au-Yeung, ... Journal of the Endocrine Society 4 (Supplement_1), OR32-06, 2020 | 1 | 2020 |
| Detection, management, and prevention of diabetes-related foot disease in the Australian context S McNeil, K Waller, YSP Lorenzo, OC Mateevici, S Telianidis, S Qi, ... World Journal of Diabetes 14 (7), 942, 2023 | | 2023 |
| WJD S McNeil, K Waller, YSP Lorenzo, OC Mateevici, S Telianidis, S Qi, ... | | 2023 |
| FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo). A Iravani, R Wallace, S Lo, A Galligan, A Weppler, G Au-Yeung, D Kee, ... Journal of Clinical Oncology 38 (15_suppl), 10041-10041, 2020 | | 2020 |
| Key Clinical Risk Factors Identify Adverse Glycemia in Hospitalized Patients M Kyi, JE Reid, A Gorelik, SS Kumar, A Galligan, LM Rowan, ... Diabetes 67 (Supplement_1), 2018 | | 2018 |
| Glycaemic and Clinical Outcomes of a Proactive Inpatient Diabetes Service (Rapids): A Cluster Randomised Controlled Trial M Kyi, PG Colman, PR Wraight, J Reid, A Gorelik, A Galligan, S Kumar, ... Available at SSRN 3204721, 2018 | | 2018 |
